Pediatric Acute Ischemic Stroke by Age-Group: A Systematic Review and Meta-Analysis of Published Studies and

Denise M Oleske1, Xianbin Cheng2, Anna Jeong3

  • 1Global Epidemiology, AbbVie, North Chicago, Illinois, USA.

Neuroepidemiology
|August 31, 2021
PubMed

Insights

Pediatric acute ischemic stroke (AIS) is rare but serious. Incidence rates show a reverse J-shaped curve, highest in neonates and older children, with significant variation by country.

Area of Science:

  • Pediatric Neurology
  • Epidemiology
  • Public Health

Background:

  • Pediatric stroke, though rare, carries severe consequences.
  • Etiologic factors for acute ischemic stroke (AIS) in children vary with age.
  • Systematic examination of pediatric AIS incidence by age subgroup is needed.

Approach:

  • Conducted a systematic literature review (1983-2020) and analyzed European/US hospitalization records (2015-2018).
  • Collated data on AIS diagnosis codes and age-specific incidence rates for children aged 0-17/18 years.
  • Performed meta-analysis to assess heterogeneity of AIS rates in neonates.

Key Points:

  • Pooled AIS incidence rate was 4.6 per 100,000 children (full age range).
  • Incidence varied significantly by country, from 7.0 (Germany) to 1.3 (Denmark) per 100,000.
  • Highest rates observed in neonates (24.6/100,000), declining in early childhood, and rising in adolescence.

Conclusions:

  • Pediatric AIS incidence follows a reverse J-shaped curve, peaking in neonates and adolescents.
  • Consistent pattern observed primarily in European and North American countries.
  • Further research is needed to explore geographic variations and identify age-specific risk factors.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
47
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
42
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
52